Loading clinical trials...
Loading clinical trials...
To evaluate the safety and efficacy of fingolimod 0.5mg vs. placebo in MS patients in China
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Novartis Pharmaceuticals
NCT07006805 · Relapsing Multiple Sclerosis (RMS), Progressive Multiple Sclerosis (PMS), and more
NCT01518660 · Multiple Sclerosis (Relapsing Remitting)
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions